tradingkey.logo


tradingkey.logo


Neuronetics Inc

STIM
1.242USD
-0.088-6.65%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
20.17MāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
āļ‚āļēāļ”āļ—āļļāļ™P/E TTM


āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ Neuronetics Inc āļšāļĢāļīāļĐāļąāļ—

Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.

āļ‚āđ‰āļ­āļĄāļđāļĨ Neuronetics Inc


āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™STIM
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—Neuronetics Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 28, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Keith J. Sullivan
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™716
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Jun 28
āļ—āļĩāđˆāļ­āļĒāļđāđˆ3222 Phoenixville Pike
āđ€āļĄāļ·āļ­āļ‡MALVERN
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ OMX - NASDAQ BASIC
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ19355
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ18776007555
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://neurostar.com/neuronetics/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™STIM
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļJun 28, 2018
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Keith J. Sullivan

āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—āļ‚āļ­āļ‡ Neuronetics Inc


āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
845.21K
+2.96%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.79%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.25%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+3.95%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+21.29%
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
845.21K
+2.96%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.79%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.25%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+3.95%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+21.29%

āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰

āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 6 āļĄ.āļ„.
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
36.25M
97.19%
International
1.05M
2.81%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆUSD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Clinic revenue
21.81M
58.47%
Treatment sessions
10.76M
28.84%
NeuroStar Advanced Therapy System
3.96M
10.61%
Other
776.00K
2.08%

āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™

āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 27 āļĄāļĩ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļĻāļļāļāļĢāđŒāļ—āļĩāđˆ 27 āļĄāļĩ.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Madryn Asset Management, LP
29.93%
Chernett (Jorey)
12.84%
Parian Ultreia LP
6.99%
UBS Financial Services, Inc.
3.76%
The Vanguard Group, Inc.
3.73%
āļ­āļ·āđˆāļ™ āđ†
42.74%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Madryn Asset Management, LP
29.93%
Chernett (Jorey)
12.84%
Parian Ultreia LP
6.99%
UBS Financial Services, Inc.
3.76%
The Vanguard Group, Inc.
3.73%
āļ­āļ·āđˆāļ™ āđ†
42.74%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Private Equity
29.93%
Individual Investor
22.80%
Investment Advisor
16.61%
Hedge Fund
10.29%
Corporation
6.99%
Investment Advisor/Hedge Fund
4.65%
Research Firm
2.28%
Venture Capital
0.45%
Bank and Trust
0.13%
āļ­āļ·āđˆāļ™ āđ†
5.86%

āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļžāļĪāļŦāļąāļŠāļ—āļĩāđˆ 1 āļĄ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q4
216
42.35M
61.84%
-15.92M
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™


āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
Madryn Asset Management, LP
20.74M
30.28%
-3.50M
-14.44%
Aug 08, 2025
Chernett (Jorey)
4.40M
6.43%
+4.40M
--
Nov 17, 2025
UBS Financial Services, Inc.
2.16M
3.16%
+1.85M
+580.70%
Sep 30, 2025
The Vanguard Group, Inc.
2.83M
4.14%
+89.50K
+3.26%
Sep 30, 2025
Balyasny Asset Management LP
1.82M
2.66%
+312.55K
+20.71%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
2.12M
3.1%
+75.30K
+3.68%
Sep 30, 2025
Cucuz (Sasha)
2.03M
2.97%
+6.41K
+0.32%
Oct 20, 2025
Sullivan (Keith J)
1.61M
2.35%
--
--
Mar 24, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ

ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡


āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 6 āļ˜.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
AdvisorShares Psychedelics ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.31%
Invesco NASDAQ Future Gen 200 ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.43%
iShares Neuroscience and Healthcare ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.1%
Vanguard US Momentum Factor ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.04%
iShares Micro-Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.02%
iShares Russell 2000 Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.01%
Avantis US Small Cap Equity ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
ProShares Hedge Replication ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%
Proshares Ultra Russell 2000
āļŠāļąāļ”āļŠāđˆāļ§āļ™0%

āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ


āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ

āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™


āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™